Grants for Nonprofits - Federal

This funding opportunity provides up to $2.1 million to nonprofit organizations for training health care providers on preventing and treating pesticide-related illnesses, particularly for vulnerable populations like farmworkers.

This grant provides funding to neuroscience researchers to advance their small molecule drug discovery and development projects aimed at treating disorders of the nervous system.

To increase research capacity for NF, the NFRP is offering the NFRA. The intent of the NFRA is to provide a framework of intensive mentoring and iterative guidance with proposed research, national networking, collaborations, and a peer group of junior faculty (Scholars). The NFRP NFRA will bring together established NF investigators (one Director and one Deputy Director) and early-career independent investigators (Scholars) and their Career Guides to develop successful, highly productive NF scientists and clinicians that will conduct research with the aim of lessening the clinical impact of NF1, NF2, and schwannomatosis. The NFRA is a multi-institutional interactive virtual academy platform designed to offer support to NFRA Scholars with the goal to advance innovative, high impact NF research through a collaborative and career development environment.The functioning NFRA will consist of Scholars and their Career Guides (mentors) from different institutions, and an Academy Director and Deputy Director (see Figure 1 below). The Academy Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with their Career Guides, assess the progress of the Scholars, and facilitate communication and collaboration among all Academy members. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, a secondary Career Guide at the Scholars institution is needed. The NFRA will afford Scholars opportunities to operate in a collegial, highly dynamic, and cutting-edge center to move early-career investigators towards positions as leaders in NF conducting impactful research.During this first phase of the academy, the NFRP is offering the FY24 NFRALA funding opportunity to solicit applications for an Academy Director and Deputy Director to lead the NFRA. The Academy Director and Deputy Director (referred to as Academy Leadership) must be established NF researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early-career independent investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars in the NFRA. An objective of the NFRA leadership team is to establish the Academy structure in its first year and in subsequent years, conduct oversight of this activity. Other objectives will include execution of research that will engage NFRA FY25 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in NF disorders. The leadership team will identify and offer opportunities to network with other NFRP FY25 Early Investigator Research Award recipients (and subsequent year awardees) and NFRP FY25 New Investigator Award Early-Stage Investigator (NIA ESI) Award recipients (and subsequent year awardees). In the second stage of the academy, the NFRP anticipates release of funding opportunities for the Scholars who will conduct their research under the guidance of the NFRA leadership team.

This grant provides funding for alumni of U.S. government-sponsored exchange programs to implement innovative social impact projects that address global challenges in areas like the environment, entrepreneurship, regional security, and democratic values.

This funding opportunity provides financial support to various organizations to assist the Botswana Ministry of Health in implementing effective HIV prevention and treatment programs, particularly for underserved populations.

The "Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations II" grant aims to expand the existing mental health research network to include larger studies, provide guidance to the scientific community, and support career development for researchers from low-resource settings worldwide.

This funding opportunity supports not-for-profit organizations and individuals in Myanmar to implement projects that promote education, entrepreneurship, media literacy, and cultural exchange with the United States.

This funding opportunity supports educational programs that promote diversity in neuroscience research by providing mentoring, research experiences, and skill development for underrepresented individuals in the field.

This grant provides funding for researchers to develop and test innovative behavioral treatments for individuals struggling with drug and alcohol misuse, particularly focusing on improving treatment effectiveness and accessibility for diverse populations.

This program will help rural hospitals expand their services to meet community health needs while increasing their revenues. The program will achieve these goals by providing expert technical assistance to rural hospitals to conduct market assessments, determine ways to enhance existing service lines, and start new service lines to keep services locally. The program will also provide direct financial support to help with associate costs of service lines. This program will also have the affect of helping facilities address long-standing rural disparities.

This funding opportunity provides financial support for organizations to implement innovative solutions that enhance resilience and disaster preparedness in vulnerable communities affected by climate change and natural disasters.

This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.

The Bureau of Counterterrorism (CT) of the U.S. Department of State is inviting applications to support the Bangladeshi initiative aimed at rehabilitating and reintegrating terrorist offenders. This program, executed by the Dhaka Metropolitan Police’s Counterterrorism and Transnational Crime unit (DMP/CTTC) in collaboration with the non-government organization Centre for Alternatives (CFA), seeks to enhance efforts in rehabilitating terrorist offenders to prevent and counter violent extremism effectively.

This grant provides funding to nonprofit organizations and government entities to deliver essential family planning and reproductive health services to low-income and underserved populations across the United States.

This funding opportunity supports U.S. and non-U.S. organizations in developing a summer camp that enhances leadership and entrepreneurship skills for Kazakh youth aged 15 to 19 who were semi-finalists for U.S. Government youth exchange programs.

This Funding Opportunity Announcement (FOA) invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. The career development will take place under the guidance of an experienced mentor in the biomedical, behavioral or clinical sciences leading to research independence. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations. This FOA invites applications from institutions with eligible faculty members to undertake special study and supervised research under a mentor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (see RFA-HL-22-011).

The Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required) aims to support licensed neurologists and neurosurgeons in the NINDS intramural program as they transition to independent academic positions while leading clinical trials and advancing their research careers in neuroscience.

The purpose of this program is to support states and tribes with implementing youth suicide prevention and early intervention strategies in schools, institutions of higher education juvenile justice systems, substance use and mental health programs, foster care systems, and other child and youth-serving organizations. SAMHSA was given the authority to address priority substance abuse treatment, prevention and mental health needs of regional and national significance through assistance (grants and cooperative agreements) to States, political subdivisions of States, Indian tribes and tribal organizations, and other public or nonprofit private entities. Under these sections, CSAT, CMHS and CSAP seek to expand the availability of effective substance abuse treatment and recovery services available to Americans to improve the lives of those affected by alcohol and drug additions, and to reduce the impact of alcohol and drug abuse on individuals, families, communities and societies and to address priority mental health needs of regional and national significance and assist children in dealing with violence and traumatic events through by funding grant and cooperative agreement projects. Grants and cooperative agreements may be for (1) knowledge and development and application projects for treatment and rehabilitation and the conduct or support of evaluations of such projects; (2) training and technical assistance; (3) targeted capacity response programs (4) systems change grants including statewide family network grants and client-oriented and consumer run self-help activities and (5) programs to foster health and development of children; (6) coordination and integration of primary care services into publicly-funded community mental health centers and other community-based behavioral health settings.

The FY24 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY24 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY24, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY24 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT942524BCRPTBCCA).The FY24 Transformative Breast Cancer Consortium Development Award provides support to: Develop the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates (e.g., building appropriate collaborations, outlining integration, research management, administrative management, and communication plans, and devising an intellectual property plan) Generate necessary preliminary data to serve as proof of concept or for project integration Acquire research resources Develop a framework of necessary statistical analysesBreast cancer consumer advocates must be active participants in the development and execution of the Transformative Breast Cancer Consortium Development Award.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Transformative Breast Cancer Consortium Development Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $0.16M to fund approximately one Transformative Breast Cancer Consortium Development Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports research projects that investigate the long-term impacts of disasters on healthcare systems serving vulnerable populations in the U.S., aiming to improve access and reduce health disparities.